First Time Loading...

Atossa Therapeutics Inc
NASDAQ:ATOS

Watchlist Manager
Atossa Therapeutics Inc Logo
Atossa Therapeutics Inc
NASDAQ:ATOS
Watchlist
Price: 1.49 USD 4.93%
Updated: Apr 23, 2024

Intrinsic Value

ATOS's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other... [ Read More ]

The intrinsic value of one ATOS stock under the Base Case scenario is 4.83 USD. Compared to the current market price of 1.49 USD, Atossa Therapeutics Inc is Undervalued by 69%.

Key Points:
ATOS Intrinsic Value
Base Case
4.83 USD
Undervaluation 69%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Atossa Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ATOS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Atossa Therapeutics Inc

Provide an overview of the primary business activities
of Atossa Therapeutics Inc.

What unique competitive advantages
does Atossa Therapeutics Inc hold over its rivals?

What risks and challenges
does Atossa Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Atossa Therapeutics Inc recently?

Summarize the latest earnings call
of Atossa Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Atossa Therapeutics Inc.

Provide P/S
for Atossa Therapeutics Inc.

Provide P/E
for Atossa Therapeutics Inc.

Provide P/OCF
for Atossa Therapeutics Inc.

Provide P/FCFE
for Atossa Therapeutics Inc.

Provide P/B
for Atossa Therapeutics Inc.

Provide EV/S
for Atossa Therapeutics Inc.

Provide EV/GP
for Atossa Therapeutics Inc.

Provide EV/EBITDA
for Atossa Therapeutics Inc.

Provide EV/EBIT
for Atossa Therapeutics Inc.

Provide EV/OCF
for Atossa Therapeutics Inc.

Provide EV/FCFF
for Atossa Therapeutics Inc.

Provide EV/IC
for Atossa Therapeutics Inc.

Show me price targets
for Atossa Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Atossa Therapeutics Inc?

How accurate were the past Revenue estimates
for Atossa Therapeutics Inc?

What are the Net Income projections
for Atossa Therapeutics Inc?

How accurate were the past Net Income estimates
for Atossa Therapeutics Inc?

What are the EPS projections
for Atossa Therapeutics Inc?

How accurate were the past EPS estimates
for Atossa Therapeutics Inc?

What are the EBIT projections
for Atossa Therapeutics Inc?

How accurate were the past EBIT estimates
for Atossa Therapeutics Inc?

Compare the revenue forecasts
for Atossa Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Atossa Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Atossa Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Atossa Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Atossa Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Atossa Therapeutics Inc with its peers.

Analyze the financial leverage
of Atossa Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Atossa Therapeutics Inc.

Provide ROE
for Atossa Therapeutics Inc.

Provide ROA
for Atossa Therapeutics Inc.

Provide ROIC
for Atossa Therapeutics Inc.

Provide ROCE
for Atossa Therapeutics Inc.

Provide Gross Margin
for Atossa Therapeutics Inc.

Provide Operating Margin
for Atossa Therapeutics Inc.

Provide Net Margin
for Atossa Therapeutics Inc.

Provide FCF Margin
for Atossa Therapeutics Inc.

Show all solvency ratios
for Atossa Therapeutics Inc.

Provide D/E Ratio
for Atossa Therapeutics Inc.

Provide D/A Ratio
for Atossa Therapeutics Inc.

Provide Interest Coverage Ratio
for Atossa Therapeutics Inc.

Provide Altman Z-Score Ratio
for Atossa Therapeutics Inc.

Provide Quick Ratio
for Atossa Therapeutics Inc.

Provide Current Ratio
for Atossa Therapeutics Inc.

Provide Cash Ratio
for Atossa Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Atossa Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Atossa Therapeutics Inc?

What is the current Free Cash Flow
of Atossa Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Atossa Therapeutics Inc.

Financials

Balance Sheet Decomposition
Atossa Therapeutics Inc

Current Assets 92.2m
Cash & Short-Term Investments 88.5m
Other Current Assets 3.8m
Non-Current Assets 4m
Long-Term Investments 1.7m
Other Non-Current Assets 2.3m
Current Liabilities 5.2m
Accounts Payable 806k
Accrued Liabilities 2.6m
Other Current Liabilities 1.8m
Efficiency

Earnings Waterfall
Atossa Therapeutics Inc

Revenue
0 USD
Operating Expenses
-31.4m USD
Operating Income
-31.4m USD
Other Expenses
1.3m USD
Net Income
-30.1m USD

Free Cash Flow Analysis
Atossa Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ATOS Profitability Score
Profitability Due Diligence

Atossa Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

30/100
Profitability
Score

Atossa Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

ATOS Solvency Score
Solvency Due Diligence

Atossa Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Atossa Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ATOS Price Targets Summary
Atossa Therapeutics Inc

Wall Street analysts forecast ATOS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ATOS is 4.67 USD with a low forecast of 4.04 USD and a high forecast of 6.04 USD.

Lowest
Price Target
4.04 USD
171% Upside
Average
Price Target
4.67 USD
214% Upside
Highest
Price Target
6.04 USD
305% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ATOS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ATOS Price
Atossa Therapeutics Inc

1M 1M
-21%
6M 6M
+126%
1Y 1Y
+122%
3Y 3Y
-16%
5Y 5Y
-57%
10Y 10Y
-99%
Annual Price Range
1.49
52w Low
0.6
52w High
2.1
Price Metrics
Average Annual Return -19.37%
Standard Deviation of Annual Returns 69.17%
Max Drawdown -94%
Shares Statistics
Market Capitalization 186.7m USD
Shares Outstanding 125 304 000
Percentage of Shares Shorted 8.43%

ATOS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Atossa Therapeutics Inc Logo
Atossa Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

186.7m USD

Dividend Yield

0%

Description

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 4 full-time employees. The company went IPO on 2012-11-08. The firm is focused on discovering and developing medicines for breast cancer, other breast conditions and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier. AT-H201 program is to develop a therapy to improve lung and function like a chemical vaccine. The company is also developing an oral formulation of Endoxifen to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy.

Contact

WASHINGTON
Seattle
107 Spring St
+12065880256.0
https://atossatherapeutics.com/

IPO

2012-11-08

Employees

4

Officers

Chairman, CEO & President
Dr. Steven C. Quay FCAP, M.D., Ph.D.
SVP, Finance & Principal Accounting Officer
Ms. Heather Rees
Senior Vice President of Administration & HR
Ms. Delly Behen P.H.R.
Vice President of Investor & Public Relations
Mr. Eric Van Zanten
Interim Chief Medical Officer
Dr. Richard Graydon M.D., Ph.D.

See Also

Discover More
What is the Intrinsic Value of one ATOS stock?

The intrinsic value of one ATOS stock under the Base Case scenario is 4.83 USD.

Is ATOS stock undervalued or overvalued?

Compared to the current market price of 1.49 USD, Atossa Therapeutics Inc is Undervalued by 69%.